The present invention relates to implantable devices. More specifically, the present invention relates to heart valve prosthetic devices for cardiac implantation. The present invention may also be utilized in other body cavities, vessels, or ducts.
The transport of vital fluids in the human body is largely regulated by valves. Physiological valves are designed to prevent the backflow of bodily fluids, such as blood, lymph, urine, bile, etc., thereby keeping the body's fluid dynamics unidirectional for proper homeostasis. For example, venous valves maintain the upward flow of blood, particularly from the lower extremities, back toward the heart, while lymphatic valves prevent the backflow of lymph within the lymph vessels, particularly those of the limbs.
Because of their common function, valves share certain anatomical features despite variations in relative size. The cardiac valves are among the largest valves in the body with diameters that may exceed 30 mm, while valves of the smaller veins may have diameters no larger than a fraction of a millimeter. Regardless of their size, however, many physiological valves are situated in specialized anatomical structures known as sinuses. Valve sinuses can be described as dilations or bulges in the vessel wall that houses the valve. The geometry of the sinus has a function in the operation and fluid dynamics of the valve. One function is to guide fluid flow so as to create eddy currents that prevent the valve leaflets from adhering to the wall of the vessel at the peak of flow velocity, such as during systole. Another function of the sinus geometry is to generate currents that facilitate the precise closing of the leaflets at the beginning of backflow pressure. The sinus geometry is also important in reducing the stress exerted by differential fluid flow pressure on the valve leaflets or cusps as they open and close.
Thus, for example, the eddy currents occurring within the sinuses of Valsalva in the natural aortic root have been shown to be important in creating smooth, gradual and gentle closure of the aortic valve at the end of systole. Blood is permitted to travel along the curved contour of the sinus and onto the valve leaflets to effect their closure, thereby reducing the pressure that would otherwise be exerted by direct fluid flow onto the valve leaflets. The sinuses of Valsalva also contain the coronary ostia, which are outflow openings of the arteries that feed the heart muscle. When valve sinuses contain such outflow openings, they serve the additional purpose of providing blood flow to such vessels throughout the cardiac cycle.
When valves exhibit abnormal anatomy and function as a result of valve disease or injury, the unidirectional flow of the physiological fluid they are designed to regulate is disrupted, resulting in increased hydrostatic pressure. For example, venous valvular dysfunction leads to blood flowing back and pooling in the lower legs, resulting in pain, swelling and edema, changes in skin color, and skin ulcerations that can be extremely difficult to treat. Lymphatic valve insufficiency can result in lymphedema with tissue fibrosis and gross distention of the affected body part. Cardiac valvular disease may lead to pulmonary hypertension and edema, atrial fibrillation, and right heart failure in the case of mitral and tricuspid valve stenosis; or pulmonary congestion, left ventricular contractile impairment and congestive heart failure in the case of mitral regurgitation and aortic stenosis. Regardless of their etiology, all valvular diseases result in either stenosis, in which the valve does not open properly, impeding fluid flow across it and causing a rise in fluid pressure, or insufficiency/regurgitation, in which the valve does not close properly and the fluid leaks back across the valve, creating backflow. Some valves are afflicted with both stenosis and insufficiency, in which case the valve neither opens fully nor closes completely.
Because of the potential severity of the clinical consequences of valve disease, valve replacement surgery is becoming a widely used medical procedure, described and illustrated in numerous books and articles. When replacement of a valve is necessary, the diseased or abnormal valve is typically cut out and replaced with either a mechanical or tissue valve. A conventional heart valve replacement surgery involves accessing the heart in a patient's thoracic cavity through a longitudinal incision in the chest. For example, a median sternotomy requires cutting through the sternum and forcing the two opposite halves of the rib cage to be spread apart, allowing access to the thoracic cavity and the heart within. The patient is then placed on cardiopulmonary bypass, which involves stopping the heart to permit access to the internal chambers. Such open heart surgery is particularly invasive and involves a lengthy and difficult recovery period. Reducing or eliminating the time a patient spends in surgery is thus a goal of foremost clinical priority.
One strategy for reducing the time spent in surgery is to eliminate or reduce the need for suturing a replacement valve into position. Toward this end, valve assemblies that allow implantation with minimal or no sutures would be greatly advantageous. Attaching a valve such as a tissue valve to a support structure such as a stent may enable a valve assembly that allows implantation with minimal or no sutures. It is important that such valve constructs are configured such that the tissue leaflets or the support valve don't come into contact with the support structure, either during the collapsed or expanded state, or both in order to prevent abrasion. Such contact is capable of contributing undesired stress on the valve leaflet. Moreover, it is advantageous that such support structures are configured to properly support a tissue valve having a scalloped inflow annulus such as that disclosed in the U.S. patent application Ser. No. 09/772,526, issued as U.S. Pat. No. 6,682,559 on Jan. 27, 2004, which is incorporated by reference herein in its entirety.
Accordingly, there is a need for a valve replacement system comprising a collapsible and expandable valve assembly that is capable of being secured into position with minimal or no suturing; facilitating an anatomically optimal position of the valve; maintaining an open pathway for other vessel openings of vessels that may be located in the valvular sinuses; and minimizing or reducing stress to the tissue valve leaflets. The valves of the present invention may comprise a plurality of joined leaflets with a corresponding number of commissural tabs. Generally, however, the desired valve will contain two to four leaflets and commissural tabs. Examples of other suitable valves are disclosed in U.S. patent application Ser. No. 09/772,526, issued as U.S. Pat. No. 6,682,559 on Jan. 27, 2004, Ser. No. 09/853,463, issued as U.S. Pat. No. 6,682,558 on Jan. 27, 2004, Ser. No. 09/924,970, issued as U.S. Pat. No. 6,673,109 on Jan. 6, 2004, Ser. No. 10/121,208, issued as U.S. Pat. No. 6,719,787 on Apr. 13, 2004, Ser. No. 10/122,035, issued as U.S. Pat. No. 6,736,846 on May 18, 2004, Ser. No. 10/153,286, issued as U.S. Pat. No. 6,719,789 on Apr. 13, 2004, and Ser. No. 10/153,290, issued as U.S. Pat. No. 6,718,788 on Apr. 13, 2004, the disclosures of all of which are incorporated by reference in their entirety herein. Likewise, the systems and methods disclosed in U.S. patent application Ser. No. 10/831,770, filed Apr. 23, 2004 which published as US2005/0240200 on Oct. 27, 2005, are fully incorporated by reference herein.
As mentioned above, an open-heart valve replacement is a long tedious procedure. For implantation of a bioprosthetic valve in the aortic position, a surgeon typically opens the aorta and excises the native valve. The surgeon then inserts the prosthetic valve through the opening in the aortic wall and secures the prosthesis at the junction of the aorta and the left ventricle. The inflow annulus of the valve faces the left ventricle and, relative to the surgeon's perspective, may be termed the distal annulus, while the outflow annulus of the valve faces the aorta and may be termed the proximal annulus.
An alternative procedure for approaching the left atrium and the aortic or mitral valve is by intravascular catherization from a femoral vein through the cardiac septum, which separates the right atrium and the left atrium. Yet another alternative for approaching the left atrium and the aortic or mitral valve is by intravascular catherization from a femoral artery up through aortic valve.
Andersen et al. in U.S. Pat. No. 6,582,462, entire contents of which are incorporated herein by reference, discloses a valve prosthesis for implantation in a body channel having an inner wall, the prosthesis comprising a radially collapsible and expandable cylindrical stent, the stent including a cylindrical support means having a cylinder surface; and a collapsible and expandable valve having commissural points, the valve mounted to the stent at the commissural points, wherein the stent and valve are configured to be implanted in the body by way of catheterization. It is one aspect of the present invention to utilize a balloon expandable stent coupled with a tissue valve. An alternative embodiment in the present invention to utilizing a balloon expandable stent is to utilize a self-expandable stent. Yet another alternative embodiment of the present invention to utilizing a balloon expandable stent is to utilize a stent that may be expanded with mechanical means.
Sterman et al. in U.S. Pat. No. 6,283,127, entire contents of which are incorporated herein by reference, discloses a device system and methods facilitating intervention within the heart or great vessels without the need for a median sternotomy or other form of gross thoracotomy, substantially reducing trauma, risk of complication, recovery time, and pain for the patient. Using the device systems and methods of the invention, surgical procedures may be performed through percutaneous penetrations within intercostal spaces of the patient's rib cage, without cutting, removing, or significantly displacing any of the patient's ribs or sternum. The device systems and methods are particularly well adapted for heart valve repair and replacement, facilitating visualization within the patient's thoracic cavity, repair or removal of the patient's natural valve, and, if necessary, attachment of a replacement valve in the natural valve position.
Haluck in U.S. Pat. No. 6,685,724, entire contents of which are incorporated herein by reference, discloses a surgical instrument for use in performing endoscopic procedures having a handle and an elongate tubular member having a proximal end coupled with the handle for being disposed externally of the anatomical cavity and a distal end for being disposed within the anatomical cavity. The distal end further includes a pair of opposed, relatively movable jaws that form a grasping portion operable by manipulation of the handle to releasably grasp a releasable trocar. The releasable trocar has a complementarily shaped shank, a relatively sharp tip and may include a pair of blunt-edge tissue separators that project outwardly from the outer surface of the trocar.
Endoscopic and minimally invasive medical procedures, such as laparoscopy, have become widely accepted for surgery and illness diagnosis. This is due to reduced trauma to the patient and reduced hospitalization time. Other techniques exist for creating a working space within the body cavity. At the beginning of most laparoscopic cases, a small incision is made, followed by a small (about 1 cm) port in the remaining layers of the tissue wall so as to gain access to the cavity.
Hunsberger in U.S. Pat. No. 6,613,063, entire contents of which are incorporated herein by reference, discloses a trocar assembly which includes a shank having a distal end and a proximal end, and a planar piercing blade having two substantially flat faces and a cutting contour, where the piercing blade is integrally attached to the distal end of the shank. The shank tapers inwardly towards the opposed flat faces of the piercing blade.
Further, McFarlane in U.S. Pat. No. 6,478,806, entire contents of which are incorporated herein by reference, discloses a tissue penetrating instrument of the type used in the medical field and which may or may not be embodied in the form of an obturator associated with a trocar assembly, wherein the instrument includes an elongated shaft having a penetrating tip mounted on one end thereof. The penetrating tip includes a base secured to the one end of the shaft and a distal extremity spaced longitudinally outward from the base and formed into an apex which may be defined by a point or other configuration specifically structured to facilitate penetration or puncturing of bodily tissue.
Spenser et al. disclose in U.S. patent application Ser. No. 09/975,750, issued as U.S. Pat. No. 6,893,460 on May 17, 2005, Ser. No. 10/270,252, issued as U.S. Pat. No. 6,730,118 on May 4, 2004, and Ser. No. 10/637,882, which published as US2004-0039436 on Feb. 26, 2004, the entire contents of which are incorporated herein by reference, disclose and implantable prosthetic valve that comprises a support sent to be initially crimped in a narrow configuration suitable for catherization through the body duct to a target location.
Key features of any valve where sutures to hold the replacement valve into position are to be eliminated or reduced are: durability, low-pressure gradient across the valve, sufficient seal around the valve to prevent perivalvular leak, and prevent migration. Therefore, it would be desirable to provide an implantable valve that with features that aim to increase durability, reduce pressure gradient across the valve, and provide an adequate seal around the valve and prevent migration.
The present invention provides a valve prosthesis that in one embodiment comprises a support stent, comprised of a deployable construction adapted to be initially crimped in a narrow configuration suitable for catherization through the body ducts to a target location and adapted to be deployed by exerting substantially radial forces from within by means of a deployment device to a deployed state in the target location, the support stent provided with a plurality of longitudinally rigid support beams of fixed length; and a valve assembly comprising a flexible conduit having an inlet end and an outlet, made of pliant material attached to the support beams providing collapsible slack portions of the conduit at the outlet, whereby when flow is allowed to pass through the valve prosthesis device from the inlet to the outlet the valve assembly is kept in an open position whereas a reverse flow is prevented as the collapsible slack portions of the valve assembly collapse inwardly providing blockage to the reverse flow.
In another embodiment of the present invention, the support stent comprises an annular frame.
In yet another embodiment of the present invention, the support stent is made out of stainless steel.
In yet another embodiment of the present invention, said valve assembly has a tricuspid configuration.
In yet another embodiment of the present invention, said valve assembly is made from biocompatible material.
In yet another embodiment of the present invention, the valve assembly is made from pericardial tissue, or other biological tissue.
In yet another embodiment of the present invention, said valve assembly is made from biocompatible polymers.
In yet another embodiment of the present invention, the valve assembly is made from materials selected from the group consisting of polyurethane and polyethylene terphthalane.
In yet another embodiment of the present invention, the valve assembly comprises a main body made from polyethylene terphthalane and leaflets made from polyurethane.
In yet another embodiment of the present invention, said support stent is made from nickel titanium alloys.
In yet another embodiment of the present invention, the support beams are substantially equidistant and substantially parallel so as to provide anchorage for the valve assembly.
In yet another embodiment of the present invention, the support beams are provided with bores so as to allow stitching or tying of the valve assembly to the beams.
In yet another embodiment of the present invention, the support beams are not provided with bores so as to allow extra rigidity to the valve support structures.
In yet another embodiment of the present invention, the support beams are chemically adhered to the support stent.
In yet another embodiment of the present invention, said valve assembly is riveted to the support beams.
In yet another embodiment of the present invention, said beams are manufactured by injection using a mold, or by machining.
In yet another embodiment of the present invention, said valve assembly is rolled over the support stent at the inlet.
In yet another embodiment of the present invention, said valve device is manufactured using forging or dipping techniques.
In yet another embodiment of the present invention, said valve assembly leaflets are longer than needed to exactly close the outlet, thus when they are in the collapsed state substantial portions of the leaflets fall on each other creating better sealing.
In yet another embodiment of the present invention, said valve assembly is made from coils of a polymer, coated by a coating layer of same polymer.
In yet another embodiment of the present invention, said polymer is polyurethane.
In yet another embodiment of the present invention, the support stent is provided with heavy metal markers so as to enable tracking and determining the valve device position and orientation.
In yet another embodiment of the present invention, the heavy metal markers are selected from gold, platinum, iridium, tantalum, cobalt, chrome, and titanium alloys.
In yet another embodiment of the present invention, the valve assembly leaflets are provided with radio-opaque materials at the outlet so as to help tracking the valve device operation in vivo.
In yet another embodiment of the present invention, said radio-opaque material comprises gold thread.
In yet another embodiment of the present invention, the diameter of said support stent when fully deployed is in the range of from about 15 to about 33 mm.
In yet another embodiment of the present invention, the diameter of said support stent may be expanded from about 4 to about 25 mm.
In yet another embodiment of the present invention, the diameter of said support stent may be expanded from about 10 mm to about 25 mm.
In yet another embodiment of the present invention, the support beams are provided with bores and wherein the valve assembly is attached to the support beams by means of U-shaped rigid members that are fastened to the valve assembly and that are provided with extruding portions that fit into matching bores on the support beams.
In yet another embodiment of the present invention, the support beams comprise rigid support beams in the form of frame construction, and the valve assembly pliant material is inserted through a gap in the frame and a fastening rod is inserted through a pocket formed between the pliant material and the frame and holds the valve in position.
In yet another embodiment of the present invention, the main body of the valve assembly is made from coiled wire coated with coating material.
In yet another embodiment of the present invention, the coiled wire and the coating material is made from polyurethane.
In yet another embodiment of the present invention, a strengthening wire is interlaced in the valve assembly at the outlet of the conduit so as to define a fault line about which the collapsible slack portion of the valve assembly may flap.
In yet another embodiment of the present invention, the strengthening wire is made from nickel titanium alloy.
In yet another embodiment of the present invention, there is provided a valve prosthesis device suitable for implantation in body ducts, the device comprising a main conduit body having an inlet and an outlet and pliant leaflets attached at the outlet so that when a flow passes through the conduit from the inlet to the outlet the leaflets are in an open position allowing the flow to exit the outlet, and when the flow is reversed the leaflets collapse so as to block the outlet, wherein the main body is made from polyethylene terphtalate and collapsible leaflets are made from polyurethane.
In yet another embodiment of the present invention, support beams made from polyurethane are provided on the main body and wherein the leaflets are attached to the main body at the support beams.
In yet another embodiment of the present invention, said support beams are chemically adhered to the main body.
In yet another embodiment of the present invention, there is provided a valve prosthesis device suitable for implantation in body ducts, the device comprising:
A support stent, comprised of a deployable construction adapted to be initially crimped in a narrow configuration suitable for catherization through the body duct to a target location and adapted to be deployed by exerting substantially radial force from within by means of a deployment device to a deployed state in the target location, the support stent provided with a plurality of longitudinally rigid support beams of fixed length; a valve assembly comprising a flexible conduit having an inlet and an outlet, made of pliant material attached to the support beams providing collapsible slack portions of the conduit at the outlet; and substantially equidistant rigid support beams interlaced or attached to the slack portion of the valve assembly material, arranged longitudinally
In yet another embodiment of the present invention, the multiple plates are adapted to move simultaneously by means of a lever and transmission.
In yet another embodiment of the present invention, there is provided a method for deploying an implantable prosthesis valve device at the natural aortic valve position at the entrance to the left ventricle of a myocardium of a patient, the method comprising the steps of: (a) providing a balloon catheter having a proximal end and a distal end, having a first and second independently inflatable portions, the first inflatable portion located at the distal end of the catheter and the second inflatable portion adjacently behind the first inflatable portion; (b) providing a guiding tool for guiding the balloon catheter in the vasculature of the patient; (c) providing a deployable implantable valve prosthesis device adapted to be mounted on the second inflatable portion of the balloon catheter; (d) guiding the balloon catheter through the patient's aorta using the guiding tool, the valve device mounted over the second inflatable portion of the balloon catheter until the first inflatable portion of the balloon catheter is inserted into the left ventricle, whereas the second inflatable portion of the balloon catheter is positioned at the natural aortic valve position; (e) inflating the first inflatable portion of the balloon catheter so as to substantially block blood flow through the natural aortic valve and anchor the distal end of the balloon catheter in position; (f) inflating the second inflatable portion of the balloon catheter so as to deploy the implantable prosthesis valve device in position at the natural aortic valve positions; (g) deflating the first and second inflatable portions of the balloon catheter; and (h) retracting the balloon catheter and removing it from the patient's body.
In yet another embodiment of the present invention, the guiding tool compromises a guide wire.
In some further embodiments, the present invention provides a method for deploying an implantable prosthesis valve device at the natural aortic valve position at the entrance to the left ventricle of the myocardium of a patient, the method comprising the steps of: (a) providing a balloon catheter having a proximal end a distal end, having a first and second independently inflatable portions, the first inflatable portion located at the distal end of the catheter and the second inflatable portion adjacently behind the first inflatable portion; (b) providing a guiding tool for guiding the balloon catheter in the vasculature of the patient; providing a deployable implantable valve prosthesis device adapted to be mounted on the first inflatable portion of the balloon catheter, and a deployable annular stent device adapted to be mounted over the second inflatable portion of the balloon catheter, the deployable implantable valve prosthesis device and the deployable annular stent kept at a predetermined distance apart; (d) guiding the balloon catheter through the patient's aorta using the guiding tool, the valve device mounted over the first inflatable portion of the balloon catheter and the deployable annular stent mounted over the second inflatable portion of the balloon catheter, until the first inflatable portion of the balloon catheter is positioned at the natural aortic valve position; (e) inflating the second inflatable portion of the balloon catheter so that the deployable stent device is deployed within the aorta thus anchoring the deployable annular stent and the coupled valve device in position; (f) inflating the first inflatable portion of the balloon catheter so as to deploy the implantable prosthesis valve device in position at the natural aortic valve position; (g) deflating the first and second inflatable portions of the balloon catheter; and (h) retracting the balloon catheter and removing it from the patient's body.
It is one object of the valve device described in the present invention to presents a novel means of attaching a tissue valve to a support structure. The means of attaching the valve to the support structure may increase the durability of the valve, reduce the pressure gradient across the valve, provide a seal around the valve to prevent perivalvular leak, and prevent migration. The valves of the present invention may comprise a plurality of joined leaflets with a corresponding number of commissural tabs. Generally, however, the desired valve will contain two to four leaflets and commissural tabs.
In an embodiment of the present invention, the valves are similar to the valves disclosed in U.S. patent application Ser. Nos. 09/772,526, 09/853,463, 09/924,970, 10/121,208, 10/122,035, 10/153,286, 10/153,290, the disclosures of all of which are incorporated by reference in their entirety herein. The diameter of the valves described in these applications may be equal or less than the orifice diameter of the support structure of the valve.
In yet another embodiment of the present invention, the valves described in U.S. patent application Ser. Nos. 09/772,526, 09/853,463, 09/924,970, 10/121,208, 10/122,035, 10/153,286, 10/153,290, the valves are sized such that the effective valve diameter is 1-5 mm less than the diameter of the orifice of the support structures of the valve. This size will help prevent the valve leaflets from hitting the support structure.
In yet another embodiment of the present invention, the valves are made of equine pericardium.
In yet another embodiment of the present invention, a cuff (e.g. cloth) portion of the valve assembly is wrapped around the support stent at the inlet. This may enhance stability of the stent, but further, the cuff portion described in the current invention may be used for attaching sutures. Most importantly, the cuff portion of the present invention is intended to reduce perivalvular leak around the valve. Using such a cuff to create a seal between the valve structure and the aorta prevents perivalvular leak and is especially important in patients whose annulus (or landing zone for the valve) is calcified or irregular. The cuff may also prevent migration of the valve as the friction between the valve device and the surrounding is increased. Utilizing a cloth cuff may also induce tissue ingrowth. The cloth may initially clot when it is exposed to blood. The cloth may further induce endothelial and fibroblast, and hence tissue ingrowth into the cloth cuff.
In yet another embodiment of the present invention the cloth cuff creates a step between a thin cloth covering around the inlet portion of the valve assembly that moves up to a much thicker cloth cuff slightly further downstream in the assembly. Such a “lip” or “step” may help position and secure the valve prosthesis at the correct position.
In yet other embodiments of the present invention, the scalloped inflow edge described in U.S. application Ser. Nos. 09/772,526, 09/853,463, 09/924,970, 10/121,208, 10/122,035, 10/153,286, 10/153,290, is sutured onto the cuff portion of the valve assembly described above. Another use of the cuff is thus to allow a valve with a scalloped inflow edge to be attached to a non-scalloped stent.
In yet other embodiments of the present invention, the support beams of the stent are extended at the inflow portion to accommodate the length of longer valves such as the ones described in U.S. application Ser. Nos. 09/772,526, 09/853,463, 09/924,970, 10/121,208, 10/122,035, 10/153,286, 10/153,290.
In yet another embodiment of the present invention, the support beams form eyelets at the outflow edge that the tabs of the valves described in U.S. application Ser. Nos. 09/772,526, 09/853,463, 09/924,970, 10/121,208, 10/122,035, 10/153,286, 10/153,290 may be attached to. The valve tabs may be sutured to the eyelets around the perimeter of the eyelet. Such a configuration helps distribute the stress around the tabs and reduce the wear and tear on the commissural posts of the valve.
In yet another embodiment of the present invention, the support beam eyelets described above are covered with cloth. Covering the eyelets and tabs with cloth may help induce tissue ingrowth.
In yet another embodiment of the present invention, the valve device is made such that it cannot be crimped down beyond the diameter of a typical femoral artery or a femoral vein (where the catheter can typically be no more than 8 mm). In other words, the valve device is made such that it cannot be implanted through the femoral artery or femoral vein.
In yet another embodiment of the present invention, the valve device is crimped just after it has been manufactured, and shipped from the manufacturer in the crimped state to the hospital or where it is to be implanted.
In yet another embodiment of the present invention, the stent is made out of a memory shaped metal or a memory shaped polymer.
In yet another embodiment of the present invention, the stent of the valve device is made to be balloon expandable.
In yet another embodiment of the present invention, the stent of the valve device is made to be self-expandable.
The present invention provides systems and devices for the replacement of physiological valves. In one embodiment of the present invention, the replacement valve assemblies are adapted to fit substantially within the valve sinuses. Because the devices and procedures provided by the present invention eliminate or reduce the need for suturing, time spent in surgery is significantly decreased, and the risks associated with surgery are minimized. Further, the devices of the present invention are suitable for delivery by cannula or catheter.
In yet another embodiment of the present invention, the stent of the valve device is made such as to expand into the sinus regions during balloon expansion.
In yet another embodiment of the present invention, the stent of the valve devices is made such as to expand into the sinus region during self-expansion.
In one embodiment of the present invention a valve anchoring structure is provided that is dimensioned to be placed substantially within the valve sinus. In this embodiment, the valve anchoring structure extends substantially across the length of the valve sinus region.
In another embodiment of the present invention a valve assembly is provided, comprising a valve and anchoring structure, in which the valve comprises a body having a proximal end and a distal end, an inlet at the proximal end, and an outlet at the distal end. The inlet comprises an inflow annulus, with either a scalloped or straight edge. The outlet comprises a plurality of tabs that are supported by the anchoring means at the distal end. In an embodiment of the invention, the plurality of tabs is spaced evenly around the circumference of the valve.
In yet another embodiment of the present invention, a valve assembly is provided in which there is minimal or no contact between the valve and anchoring structure.
In still another embodiment of the present invention, a valve assembly is provided in which the valve is capable of achieving full opening and full closure without contacting the anchoring structure.
In yet another embodiment of the present invention, a valve assembly is provided in which the vertical components of the anchoring structure are limited to the commissural posts between sinus cavities, thereby minimizing contact between mechanical components and fluid, as well as providing flow to vessels located in the valve sinus.
In still another embodiment of the present invention, a valve is provided that firmly attaches to the valve sinus, obviating the need for suturing to secure the valve placement.
In a further embodiment of the present invention, a valve assembly is provided in which the anchoring structure may be collapsed to at least fifty percent of its maximum diameter.
In still a further embodiment of the present invention, an expansion and contraction device is provided to facilitate implantation of the valve and anchoring structure.
In another embodiment, the present invention provides adhesive means for securing the valve assembly in a valve sinus.
In yet another embodiment of the present invention, a valve sizing apparatus is provided for the noninvasive determination of native valve size.
To better understand the present invention and appreciate its practical applications, the following Figures are provided and referenced hereafter. It should be noted that the Figures are given as examples only and in no way limit the scope of the invention.
A main aspect of the present invention is the introduction of several novel designs for an implantable prosthesis valve. Another aspect of the present invention is the disclosure of several manufacture methods for the manufacturing of implantable prosthesis valves in accordance with the present invention. A further aspect of the present invention is the provision of novel deployment and positioning techniques suitable for the valve of the present invention.
Basically the implantable prosthetic valve of the present invention comprises a leafed-valve assembly, preferably tricuspid but not limited to tricuspid valves only, consisting of a conduit having an inlet end and an outlet, made of pliant material arranged so as to present collapsible walls at the outlet. The valve assembly is mounted on a support structure such as a stent adapted to be positioned at a target location within the body duct and deploy the valve assembly by the use of deploying means, such as a balloon catheter or similar devices. In embodiments suitable for safe and convenient percutaneous positioning and deployment the annular frame is able to be posed in two positions, a crimped position where the conduit passage cross-section presented is small so as to permit advancing the device towards its target location, and a deployed position where the frame is radial extended by forces exerted from within (by deploying means) so as to provide support against the body duct wall, secure the valve in position and open itself so as to allow flow through the conduit.
The valve assembly can be made from biological matter, such as a natural tissue, pericardial tissue or other biological tissue. Alternatively, the valve assembly may be made form biocompatible polymers or similar materials. Homograph biological valves need occasional replacement (usually within 5 to 14 years) and this is a consideration the surgeon must take into account, when selecting the proper valve implant according to the patient type. Metal mechanical valves, which have better durability qualities, carry the associated risk of long-term anticoagulation treatment.
The frame can be made from shape memory alloys such as nickel titanium (nickel titanium shape memory alloys, or NiTi, as marketed, for example, under the brand name Nitinol), or other biocompatible metals. The percutaneously implantable embodiment of the implantable valve of the present invention has to be suitable for crimping into a narrow configuration for positioning and expandable to a wider, deployed configuration so as to anchor in position in the desired target location.
The support stent is preferably annular, but may be provided in other shapes too, depending on the cross-section shape of the desired target location passage.
Manufacturing of the implantable prosthetic valve of the present invention can be done in various methods, for example, by dipping, injection, electrospinning, rotation, ironing, or pressing.
The attachment of the valve assembly to the support stent can be accomplished in several ways, such as by sewing it to several anchoring points on the support stent, or riveting it, pinning it, or adhering it, to provide a valve assembly that is cast or molded over the support stent, or use any other suitable way of attachment.
To prevent leakage from the inlet it is optionally possible to roll up some slack wall of the inlet over the edge of the frame so as to present rolled-up sleeve-like portion at the inlet.
Furthermore, floating supports may be added to enhance the stability of the device and prevent it from turning inside out.
An important aspect of certain embodiments of the present invention is the provision of rigid support beams incorporated with the support stent that retains its longitudinal dimension while the entire support stent may be longitudinally or laterally extended.
The aforementioned embodiments as well as other embodiments, manufacturing methods, different designs and different types of devices are discussed and explained below with reference to the accompanying drawings. Note that the drawings are only given for the purpose of understanding the present invention and presenting some preferred embodiments of the present invention, but this does in no way limit the scope of the present invention as defined in the appended claims.
Reference is now made to
Note that the entire valve structure is adapted to be radially crimped and radially expanded, and this lends to provide ease of navigation through narrow passages in the vasculature during positioning of the device and adequate deployment on the final location. This is made possible by the provision of a collapsible support stent structure. However, the support beams always maintain the same length. Because the support beams maintain the same length, the distance between the inflow edge and the tab attachments of the valve are maintained during crimping and expansion. This allows the valve to function properly. In prior art implantable valve devices the entire support structure changes its dimensions from its initial first crimped position and final deployed position, and this means that in the attachment of the valve assembly to the support structure one must take into consideration these dimension changes and leave slack material so that upon deployment of the device the valve assembly does not tear or deform. In the valve device of the present invention there is no relative movement between the valve assembly and the support beams (along the longitudinal central axis of the device). As a result, the valve device of the present invention acquires greater durability and is capable of withstanding the harsh conditions prevailing within the heart. The novel design of the valve device of the present invention leads to longitudinal strength and rigidity whereas its collapsible support structure results in radial flexibility.
A typical size of an aortic prosthesis valve is from about 19 to about 31 mm in diameter. A maximal size of a catheter inserted into the femoral artery should be no more than 8 mm in diameter. The present invention introduces a device, which has the ability to change its diameter from about 4 mm to about 33 mm. Artificial valves are not new; however, artificial valves in accordance with the present invention posses the ability to change shape and size for the purpose of delivery and as such are novel. These newly designed valves require new manufacturing methods and technical inventions and improvements, some of which were described herein.
As described before, one embodiment of the present invention is to make it impossible for the stent to be crimped down below the size of the femoral artery or vein. In other words, one may create mechanical stops or add tissue or cloth in a manner as to prevent the stent from being capable of being crimped further down than beyond the size of the femoral artery or vein. In this manner, the stent is made such that it intentionally cannot be used through a femoral vein or femoral artery access. Creating such size constraints on the valve assembly may make it possible to create a sturdier device for prolonging the longevity of the valve assembly. Such a device could be implanted through the apex of the heart, as described in details in a U.S. patent application no. 10/831,770 submitted Apr. 23, 2004 entitled “Method and System for Cardiac Valve Delivery”. An early version of this document is submitted at the same time as the current provisional. No application number exists at this point. The application is appended to this provisional patent application, and is hereby included in this application in its entirety.
As mentioned earlier, the material of which the valve is made from can be either biological or artificial. In any case new technologies are needed to create such a valve.
To attach the valve to the body, the blood vessels determine the size during delivery, and the requirements for it to work efficiently, there is a need to mount it on a collapsible construction which can be crimped to a small size, be expanded to a larger size, and be strong enough to act as a support for the valve function. This construction, which is in somewhat similar to a large “stent”, can be made of different materials such as Nitinol, biocompatible stainless steel, polymeric material or a combination of all. Special requirement for the stent are a subject of some of the embodiments discussed herein.
The mounting of the valve onto a collapsible stent is a new field of problems. New solutions to this problem are described herein.
Another major aspect of the design of the valve of the present invention is the attachment to the body.
Yet another major aspect of the valve apparatus is the attachment of the valve to the frame.
In the traditional procedure the valve is sutured in place by a complicated suturing procedure. In the case of the percutaneous procedure there is no direct access to the implantation site therefore different attachment techniques are needed.
Another new problem that is dealt herein is the delivery procedure, which is new and unique. Positioning of the device in the body in an accurate location and orientation requires special marking and measuring methods of the device and surgical site as was disclosed herein.
Artificial polymer valves require special treatment and special conditions when kept on a shelf, as well as a special sterilization procedure. One of the consequences of the shelf treatment is the need to crimp the valve during the implantation procedure. A series of devices and inventions to allow the crimping procedure are disclosed herein.
It should be clear that the description of the embodiments and attached Figures set forth in this specification serves only for a better understanding of the invention, without limiting its scope as covered by the following claims.
While the invention has been described with reference to the specific embodiments thereof, those skilled in the art will be able to make various modifications to the described embodiments of the invention without departing from the true spirit and scope of the invention. The terms and descriptions used herein are set forth by way of illustration only and are not meant as limitations. Those skilled in the art will recognize that these and other variations are possible within the spirit and scope of the invention as defined in the following claims and their equivalents.
This application is a continuation of U.S. patent application Ser. No. 11/112,757, filed Apr. 22, 2005, which claims the benefit of U.S. Provisional Application No. 60/565,118, filed Apr. 23, 2004, the entireties of which are hereby incorporated by reference
Number | Name | Date | Kind |
---|---|---|---|
3657744 | Ersek | Apr 1972 | A |
3671979 | Moulopoulos | Jun 1972 | A |
3714671 | Edwards et al. | Feb 1973 | A |
3755823 | Hancock | Sep 1973 | A |
3795246 | Sturgeon | Mar 1974 | A |
3839741 | Haller | Oct 1974 | A |
3868956 | Alfidi et al. | Mar 1975 | A |
3874388 | King et al. | Apr 1975 | A |
4035849 | Angell et al. | Jul 1977 | A |
4056854 | Boretos et al. | Nov 1977 | A |
4222126 | Boretos et al. | Sep 1980 | A |
4233690 | Akins | Nov 1980 | A |
4265694 | Boretos | May 1981 | A |
4291420 | Reul | Sep 1981 | A |
4297749 | Davis et al. | Nov 1981 | A |
4339831 | Johnson | Jul 1982 | A |
4343048 | Ross et al. | Aug 1982 | A |
4345340 | Rosen | Aug 1982 | A |
4425908 | Simon | Jan 1984 | A |
4501030 | Lane | Feb 1985 | A |
4574803 | Storz | Mar 1986 | A |
4580568 | Gianturco | Apr 1986 | A |
4592340 | Boyles | Jun 1986 | A |
4610688 | Silvestrini et al. | Sep 1986 | A |
4612011 | Kautzky | Sep 1986 | A |
4662885 | DiPisa, Jr. | May 1987 | A |
4665906 | Jervis | May 1987 | A |
4681908 | Broderick et al. | Jul 1987 | A |
4710192 | Liotta et al. | Dec 1987 | A |
4787899 | Lazarus | Nov 1988 | A |
4787901 | Baykut | Nov 1988 | A |
4796629 | Grayzel | Jan 1989 | A |
4819751 | Shimada et al. | Apr 1989 | A |
4834755 | Silvestrini et al. | May 1989 | A |
4856516 | Hillstead | Aug 1989 | A |
4872874 | Taheri | Oct 1989 | A |
4878495 | Grayzel | Nov 1989 | A |
4878906 | Lindemann et al. | Nov 1989 | A |
4883458 | Shiber | Nov 1989 | A |
4909252 | Goldberger | Mar 1990 | A |
4917102 | Miller et al. | Apr 1990 | A |
4922905 | Strecker | May 1990 | A |
4966604 | Reiss | Oct 1990 | A |
4979939 | Shiber | Dec 1990 | A |
4986830 | Owens et al. | Jan 1991 | A |
4994077 | Dobben | Feb 1991 | A |
5007896 | Shiber | Apr 1991 | A |
5026366 | Leckrone | Jun 1991 | A |
5032128 | Alonso | Jul 1991 | A |
5047041 | Samuels | Sep 1991 | A |
5059177 | Towne et al. | Oct 1991 | A |
5085635 | Cragg | Feb 1992 | A |
5089015 | Ross | Feb 1992 | A |
5152771 | Sabbaghian et al. | Oct 1992 | A |
5163953 | Vince | Nov 1992 | A |
5167628 | Boyles | Dec 1992 | A |
5258023 | Reger | Nov 1993 | A |
5272909 | Nguyen et al. | Dec 1993 | A |
5295958 | Shturman | Mar 1994 | A |
5327774 | Nguyen et al. | Jul 1994 | A |
5332402 | Teitelbaum et al. | Jul 1994 | A |
5350398 | Pavcnik et al. | Sep 1994 | A |
5370685 | Stevens | Dec 1994 | A |
5397351 | Pavcnik et al. | Mar 1995 | A |
5411552 | Andersen et al. | May 1995 | A |
5415633 | Lazarus et al. | May 1995 | A |
5431676 | Dubrul et al. | Jul 1995 | A |
5443446 | Shturman | Aug 1995 | A |
5449384 | Johnson | Sep 1995 | A |
5480424 | Cox | Jan 1996 | A |
5489294 | McVenes et al. | Feb 1996 | A |
5489297 | Duran | Feb 1996 | A |
5496346 | Horzewski et al. | Mar 1996 | A |
5500014 | Quijano et al. | Mar 1996 | A |
5507767 | Maeda et al. | Apr 1996 | A |
5545209 | Roberts et al. | Aug 1996 | A |
5545211 | An et al. | Aug 1996 | A |
5545214 | Stevens | Aug 1996 | A |
5554185 | Block et al. | Sep 1996 | A |
5575818 | Pinchuk | Nov 1996 | A |
5580922 | Park et al. | Dec 1996 | A |
5591195 | Taheri et al. | Jan 1997 | A |
5609626 | Quijano et al. | Mar 1997 | A |
5645559 | Hachtman et al. | Jul 1997 | A |
5665115 | Cragg | Sep 1997 | A |
5667523 | Bynon et al. | Sep 1997 | A |
5674277 | Freitag | Oct 1997 | A |
5702368 | Stevens et al. | Dec 1997 | A |
5713953 | Vallana et al. | Feb 1998 | A |
5716417 | Girard et al. | Feb 1998 | A |
5746709 | Rom et al. | May 1998 | A |
5749890 | Shaknovich | May 1998 | A |
5766151 | Valley et al. | Jun 1998 | A |
5782809 | Umeno et al. | Jul 1998 | A |
5800456 | Maeda et al. | Sep 1998 | A |
5800508 | Goicoechea et al. | Sep 1998 | A |
5800527 | Jansen et al. | Sep 1998 | A |
5824041 | Lenker | Oct 1998 | A |
5824043 | Cottone, Jr. | Oct 1998 | A |
5824053 | Khosravi et al. | Oct 1998 | A |
5824056 | Rosenberg | Oct 1998 | A |
5824061 | Quijano et al. | Oct 1998 | A |
5824064 | Taheri | Oct 1998 | A |
5840081 | Andersen et al. | Nov 1998 | A |
5843158 | Lenker et al. | Dec 1998 | A |
5851232 | Lois | Dec 1998 | A |
5855597 | Jayaraman | Jan 1999 | A |
5855601 | Bessler et al. | Jan 1999 | A |
5860966 | Tower | Jan 1999 | A |
5861028 | Angell | Jan 1999 | A |
5876448 | Thompson et al. | Mar 1999 | A |
5888201 | Stinson et al. | Mar 1999 | A |
5891191 | Stinson | Apr 1999 | A |
5906619 | Olson et al. | May 1999 | A |
5913842 | Boyd et al. | Jun 1999 | A |
5925063 | Khosravi | Jul 1999 | A |
5944738 | Amplatz et al. | Aug 1999 | A |
5957949 | Leonhardt et al. | Sep 1999 | A |
5968068 | Dehdashtian et al. | Oct 1999 | A |
5984957 | Laptewicz, Jr. et al. | Nov 1999 | A |
5997573 | Quijano et al. | Dec 1999 | A |
6022370 | Tower | Feb 2000 | A |
6027525 | Suh et al. | Feb 2000 | A |
6029671 | Stevens et al. | Feb 2000 | A |
6042589 | Marianne | Mar 2000 | A |
6042598 | Tsugita et al. | Mar 2000 | A |
6042607 | Williamson, IV | Mar 2000 | A |
6051014 | Jang | Apr 2000 | A |
6059809 | Amor et al. | May 2000 | A |
6110201 | Quijano et al. | Aug 2000 | A |
6146366 | Schachar | Nov 2000 | A |
6159239 | Greenhalgh | Dec 2000 | A |
6162208 | Hipps | Dec 2000 | A |
6162245 | Jayaraman | Dec 2000 | A |
6168614 | Andersen et al. | Jan 2001 | B1 |
6171335 | Wheatley et al. | Jan 2001 | B1 |
6200336 | Pavcnik et al. | Mar 2001 | B1 |
6203550 | Olson | Mar 2001 | B1 |
6210408 | Chandrasekaran et al. | Apr 2001 | B1 |
6218662 | Tchakarov et al. | Apr 2001 | B1 |
6221006 | Dubrul et al. | Apr 2001 | B1 |
6221091 | Khosravi | Apr 2001 | B1 |
6241757 | An et al. | Jun 2001 | B1 |
6245102 | Jayaraman | Jun 2001 | B1 |
6248116 | Chevilon | Jun 2001 | B1 |
6258114 | Konya et al. | Jul 2001 | B1 |
6258115 | Dubrul | Jul 2001 | B1 |
6258120 | McKenzie et al. | Jul 2001 | B1 |
6277555 | Duran et al. | Aug 2001 | B1 |
6283127 | Sterman | Sep 2001 | B1 |
6299637 | Shaolia et al. | Oct 2001 | B1 |
6302906 | Goicoechea et al. | Oct 2001 | B1 |
6309382 | Garrison et al. | Oct 2001 | B1 |
6309417 | Spence et al. | Oct 2001 | B1 |
6338735 | Stevens | Jan 2002 | B1 |
6348063 | Yassour et al. | Feb 2002 | B1 |
6350277 | Kocur | Feb 2002 | B1 |
6352708 | Duran et al. | Mar 2002 | B1 |
6371970 | Khosravi et al. | Apr 2002 | B1 |
6371983 | Lane | Apr 2002 | B1 |
6379383 | Palmaz et al. | Apr 2002 | B1 |
6380457 | Yurek et al. | Apr 2002 | B1 |
6398807 | Chouinard et al. | Jun 2002 | B1 |
6409750 | Hyodoh et al. | Jun 2002 | B1 |
6425916 | Garrison et al. | Jul 2002 | B1 |
6440164 | DiMatteo et al. | Aug 2002 | B1 |
6454799 | Schreck | Sep 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6461382 | Cao | Oct 2002 | B1 |
6468303 | Amplatz et al. | Oct 2002 | B1 |
6475239 | Campbell et al. | Nov 2002 | B1 |
6478806 | McFarlane | Nov 2002 | B2 |
6482228 | Norred | Nov 2002 | B1 |
6488704 | Connelly et al. | Dec 2002 | B1 |
6494909 | Greenhalgh | Dec 2002 | B2 |
6503272 | Duerig et al. | Jan 2003 | B2 |
6508833 | Pavcnik et al. | Jan 2003 | B2 |
6527800 | McGuckin, Jr. et al. | Mar 2003 | B1 |
6530949 | Konya et al. | Mar 2003 | B2 |
6530952 | Vesely | Mar 2003 | B2 |
6562031 | Chandrasekaran et al. | May 2003 | B2 |
6562058 | Seguin et al. | May 2003 | B2 |
6569196 | Vesely | May 2003 | B1 |
6582462 | Andersen | Jun 2003 | B1 |
6585758 | Chouinard et al. | Jul 2003 | B1 |
6592546 | Barbut et al. | Jul 2003 | B1 |
6605112 | Moll et al. | Aug 2003 | B1 |
6613063 | Hunsberger | Sep 2003 | B1 |
6613077 | Gilligan et al. | Sep 2003 | B2 |
6622604 | Chouinard et al. | Sep 2003 | B1 |
6635068 | Dubrul et al. | Oct 2003 | B1 |
6652571 | White et al. | Nov 2003 | B1 |
6652578 | Bailey et al. | Nov 2003 | B2 |
6656213 | Solem | Dec 2003 | B2 |
6663663 | Kim et al. | Dec 2003 | B2 |
6669724 | Park et al. | Dec 2003 | B2 |
6673089 | Yassour et al. | Jan 2004 | B1 |
6673109 | Cox | Jan 2004 | B2 |
6676698 | McGuckin, Jr. et al. | Jan 2004 | B2 |
6682558 | Tu | Jan 2004 | B2 |
6682559 | Myers | Jan 2004 | B2 |
6685724 | Haluck | Feb 2004 | B1 |
6685739 | DiMatteo et al. | Feb 2004 | B2 |
6689144 | Gerberding | Feb 2004 | B2 |
6689164 | Seguin | Feb 2004 | B1 |
6692512 | Jang | Feb 2004 | B2 |
6692513 | Streeter et al. | Feb 2004 | B2 |
6695878 | McGuckin, Jr. et al. | Feb 2004 | B2 |
6702851 | Chinn et al. | Mar 2004 | B1 |
6719787 | Cox | Apr 2004 | B2 |
6719788 | Cox | Apr 2004 | B2 |
6719789 | Cox | Apr 2004 | B2 |
6730118 | Spenser | May 2004 | B2 |
6730377 | Wang | May 2004 | B2 |
6733525 | Yang et al. | May 2004 | B2 |
6736846 | Cox | May 2004 | B2 |
6752828 | Thornton | Jun 2004 | B2 |
6758855 | Fulton, III et al. | Jul 2004 | B2 |
6769434 | Liddicoat et al. | Aug 2004 | B2 |
6786925 | Schoon | Sep 2004 | B1 |
6790229 | Berreklouw | Sep 2004 | B1 |
6792979 | Konya et al. | Sep 2004 | B2 |
6797002 | Spence | Sep 2004 | B2 |
6821297 | Snyders | Nov 2004 | B2 |
6830575 | Stenzel et al. | Dec 2004 | B2 |
6830584 | Seguin | Dec 2004 | B1 |
6830585 | Artof | Dec 2004 | B1 |
6846325 | Liddicoat | Jan 2005 | B2 |
6866650 | Stevens | Mar 2005 | B2 |
6872223 | Roberts | Mar 2005 | B2 |
6875231 | Anduiza et al. | Apr 2005 | B2 |
6883522 | Spence et al. | Apr 2005 | B2 |
6887266 | Williams et al. | May 2005 | B2 |
6890330 | Streeter et al. | May 2005 | B2 |
6893460 | Spenser | May 2005 | B2 |
6896690 | Lambrecht et al. | May 2005 | B1 |
6908481 | Cribier | Jun 2005 | B2 |
6913600 | Valley et al. | Jul 2005 | B2 |
6929653 | Streeter | Aug 2005 | B2 |
6936066 | Palmaz et al. | Aug 2005 | B2 |
6939365 | Fogarty et al. | Sep 2005 | B1 |
6951571 | Srivastava | Oct 2005 | B1 |
6974474 | Pavcnik et al. | Dec 2005 | B2 |
6974476 | McGuckin et al. | Dec 2005 | B2 |
6986742 | Hart et al. | Jan 2006 | B2 |
6989027 | Allen et al. | Jan 2006 | B2 |
6989028 | Lashinski et al. | Jan 2006 | B2 |
6991649 | Sievers | Jan 2006 | B2 |
7018401 | Hyodoh et al. | Mar 2006 | B1 |
7041128 | McGuckin, Jr. et al. | May 2006 | B2 |
7044966 | Svanidze et al. | May 2006 | B2 |
7048014 | Hyodoh et al. | May 2006 | B2 |
7097659 | Woolfson et al. | Aug 2006 | B2 |
7101396 | Artof et al. | Sep 2006 | B2 |
7105016 | Shui et al. | Sep 2006 | B2 |
7115141 | Menz et al. | Oct 2006 | B2 |
7128759 | Osborne et al. | Oct 2006 | B2 |
7147663 | Berg et al. | Dec 2006 | B1 |
7153324 | Case et al. | Dec 2006 | B2 |
7160319 | Chouinard et al. | Jan 2007 | B2 |
7175656 | Khairkhahan | Feb 2007 | B2 |
7186265 | Sharkawy et al. | Mar 2007 | B2 |
7195641 | Palmaz et al. | Mar 2007 | B2 |
7198646 | Figulla et al. | Apr 2007 | B2 |
7201761 | Woolfson et al. | Apr 2007 | B2 |
7201772 | Schwammenthal et al. | Apr 2007 | B2 |
7252682 | Seguin | Aug 2007 | B2 |
7300457 | Palmaz | Nov 2007 | B2 |
7300463 | Liddicoat | Nov 2007 | B2 |
7316706 | Bloom et al. | Jan 2008 | B2 |
7329278 | Seguin | Feb 2008 | B2 |
7335218 | Wilson et al. | Feb 2008 | B2 |
7338520 | Bailey et al. | Mar 2008 | B2 |
7374571 | Pease et al. | May 2008 | B2 |
7377938 | Sarac et al. | May 2008 | B2 |
7381218 | Schreck | Jun 2008 | B2 |
7384411 | Condado | Jun 2008 | B1 |
7429269 | Schwammenthal et al. | Sep 2008 | B2 |
7442204 | Schwammenthal et al. | Oct 2008 | B2 |
7462191 | Spenser et al. | Dec 2008 | B2 |
7470284 | Lambrecht et al. | Dec 2008 | B2 |
7481838 | Carpentier et al. | Jan 2009 | B2 |
7544206 | Cohn et al. | Jun 2009 | B2 |
7547322 | Sarac et al. | Jun 2009 | B2 |
7556646 | Yang et al. | Jul 2009 | B2 |
20010001314 | Davison et al. | May 2001 | A1 |
20010002445 | Vesely | May 2001 | A1 |
20010007956 | Letac et al. | Jul 2001 | A1 |
20010010017 | Letac et al. | Jul 2001 | A1 |
20010011189 | Drasler et al. | Aug 2001 | A1 |
20010021872 | Bailey et al. | Sep 2001 | A1 |
20010025196 | Chinn et al. | Sep 2001 | A1 |
20010032013 | Marton | Oct 2001 | A1 |
20010039450 | Pavcnik et al. | Nov 2001 | A1 |
20010041928 | Pavcnik et al. | Nov 2001 | A1 |
20010044647 | Pinchuk et al. | Nov 2001 | A1 |
20020010508 | Chobotov | Jan 2002 | A1 |
20020029014 | Jayaraman | Mar 2002 | A1 |
20020032480 | Spence et al. | Mar 2002 | A1 |
20020032481 | Gabbay | Mar 2002 | A1 |
20020035396 | Heath | Mar 2002 | A1 |
20020042650 | Vardi et al. | Apr 2002 | A1 |
20020052651 | Myers et al. | May 2002 | A1 |
20020058995 | Stevens | May 2002 | A1 |
20020072789 | Hackett et al. | Jun 2002 | A1 |
20020095209 | Zadno-Azizi et al. | Jul 2002 | A1 |
20020099439 | Schwartz et al. | Jul 2002 | A1 |
20020103533 | Langberg et al. | Aug 2002 | A1 |
20020107565 | Greenhalgh | Aug 2002 | A1 |
20020111674 | Chouinard et al. | Aug 2002 | A1 |
20020123802 | Snyders | Sep 2002 | A1 |
20020133183 | Lentz et al. | Sep 2002 | A1 |
20020138138 | Yang | Sep 2002 | A1 |
20020151970 | Garrison et al. | Oct 2002 | A1 |
20020161392 | Dubrul | Oct 2002 | A1 |
20020161394 | Macoviak et al. | Oct 2002 | A1 |
20020193871 | Beyersdorf et al. | Dec 2002 | A1 |
20030014104 | Cribier | Jan 2003 | A1 |
20030023300 | Bailey et al. | Jan 2003 | A1 |
20030023303 | Palmaz et al. | Jan 2003 | A1 |
20030028247 | Cali | Feb 2003 | A1 |
20030036791 | Philipp et al. | Feb 2003 | A1 |
20030040771 | Hyodoh et al. | Feb 2003 | A1 |
20030040772 | Hyodoh et al. | Feb 2003 | A1 |
20030040792 | Gabbay | Feb 2003 | A1 |
20030050694 | Yang et al. | Mar 2003 | A1 |
20030055495 | Pease et al. | Mar 2003 | A1 |
20030065386 | Weadock | Apr 2003 | A1 |
20030069492 | Abrams et al. | Apr 2003 | A1 |
20030109924 | Cribier | Jun 2003 | A1 |
20030125795 | Pavcnik et al. | Jul 2003 | A1 |
20030130726 | Thorpe et al. | Jul 2003 | A1 |
20030130729 | Paniagua et al. | Jul 2003 | A1 |
20030139804 | Hankh et al. | Jul 2003 | A1 |
20030149475 | Hyodoh et al. | Aug 2003 | A1 |
20030149476 | Damm et al. | Aug 2003 | A1 |
20030149478 | Figulla et al. | Aug 2003 | A1 |
20030153974 | Spenser et al. | Aug 2003 | A1 |
20030181850 | Diamond et al. | Sep 2003 | A1 |
20030191519 | Lombardi et al. | Oct 2003 | A1 |
20030199913 | Dubrul et al. | Oct 2003 | A1 |
20030199963 | Tower et al. | Oct 2003 | A1 |
20030199971 | Tower et al. | Oct 2003 | A1 |
20030212410 | Stenzel et al. | Nov 2003 | A1 |
20030212454 | Scott et al. | Nov 2003 | A1 |
20030225445 | Derus et al. | Dec 2003 | A1 |
20040019374 | Hojeibane et al. | Jan 2004 | A1 |
20040034411 | Quijano et al. | Feb 2004 | A1 |
20040039436 | Spenser et al. | Feb 2004 | A1 |
20040049224 | Buehlmann et al. | Mar 2004 | A1 |
20040049262 | Obermiller et al. | Mar 2004 | A1 |
20040049266 | Anduiza et al. | Mar 2004 | A1 |
20040082904 | Houde et al. | Apr 2004 | A1 |
20040088045 | Cox | May 2004 | A1 |
20040092858 | Wilson et al. | May 2004 | A1 |
20040092989 | Wilson et al. | May 2004 | A1 |
20040093005 | Durcan | May 2004 | A1 |
20040093060 | Sequin et al. | May 2004 | A1 |
20040093075 | Kuehn | May 2004 | A1 |
20040097788 | Mourles et al. | May 2004 | A1 |
20040098112 | DiMatteo et al. | May 2004 | A1 |
20040106976 | Bailey et al. | Jun 2004 | A1 |
20040106990 | Spence et al. | Jun 2004 | A1 |
20040111096 | Tu et al. | Jun 2004 | A1 |
20040116951 | Rosengart | Jun 2004 | A1 |
20040117004 | Osborne et al. | Jun 2004 | A1 |
20040122468 | Yodfat et al. | Jun 2004 | A1 |
20040122514 | Fogarty et al. | Jun 2004 | A1 |
20040122516 | Fogarty | Jun 2004 | A1 |
20040127979 | Wilson | Jul 2004 | A1 |
20040138742 | Myers et al. | Jul 2004 | A1 |
20040138743 | Myers et al. | Jul 2004 | A1 |
20040153146 | Lashinski et al. | Aug 2004 | A1 |
20040167573 | Williamson | Aug 2004 | A1 |
20040167620 | Ortiz | Aug 2004 | A1 |
20040186563 | Iobbi | Sep 2004 | A1 |
20040193261 | Berreklouw | Sep 2004 | A1 |
20040210240 | Saint | Oct 2004 | A1 |
20040210304 | Seguin et al. | Oct 2004 | A1 |
20040210307 | Khairkhahan | Oct 2004 | A1 |
20040215333 | Duran | Oct 2004 | A1 |
20040215339 | Drasler et al. | Oct 2004 | A1 |
20040225353 | McGuckin, Jr. | Nov 2004 | A1 |
20040225354 | Allen | Nov 2004 | A1 |
20040225356 | Frater | Nov 2004 | A1 |
20040254636 | Flagle et al. | Dec 2004 | A1 |
20040260389 | Case et al. | Dec 2004 | A1 |
20040260394 | Douk et al. | Dec 2004 | A1 |
20040267357 | Allen et al. | Dec 2004 | A1 |
20050010246 | Streeter | Jan 2005 | A1 |
20050010285 | Lambrecht et al. | Jan 2005 | A1 |
20050010287 | Macoviak | Jan 2005 | A1 |
20050015112 | Cohn et al. | Jan 2005 | A1 |
20050027348 | Case et al. | Feb 2005 | A1 |
20050033398 | Seguin | Feb 2005 | A1 |
20050043790 | Seguin | Feb 2005 | A1 |
20050049692 | Numamoto | Mar 2005 | A1 |
20050049696 | Siess | Mar 2005 | A1 |
20050055088 | Liddicoat et al. | Mar 2005 | A1 |
20050060029 | Le | Mar 2005 | A1 |
20050060030 | Lashinski et al. | Mar 2005 | A1 |
20050075584 | Cali | Apr 2005 | A1 |
20050075712 | Biancucci | Apr 2005 | A1 |
20050075717 | Nguyen | Apr 2005 | A1 |
20050075719 | Bergheim | Apr 2005 | A1 |
20050075724 | Svanidze | Apr 2005 | A1 |
20050075727 | Wheatley | Apr 2005 | A1 |
20050075730 | Myers | Apr 2005 | A1 |
20050075731 | Artof | Apr 2005 | A1 |
20050085841 | Eversull et al. | Apr 2005 | A1 |
20050085842 | Eversull et al. | Apr 2005 | A1 |
20050085843 | Opolski et al. | Apr 2005 | A1 |
20050085890 | Rasmussen et al. | Apr 2005 | A1 |
20050085900 | Case et al. | Apr 2005 | A1 |
20050096568 | Kato | May 2005 | A1 |
20050096692 | Linder et al. | May 2005 | A1 |
20050096724 | Stenzel et al. | May 2005 | A1 |
20050096734 | Majercak et al. | May 2005 | A1 |
20050096735 | Hojeibane et al. | May 2005 | A1 |
20050096736 | Osse et al. | May 2005 | A1 |
20050096738 | Cali et al. | May 2005 | A1 |
20050107871 | Realyvasquez et al. | May 2005 | A1 |
20050113910 | Paniagua | May 2005 | A1 |
20050119688 | Berheim | Jun 2005 | A1 |
20050131438 | Cohn | Jun 2005 | A1 |
20050137686 | Salahieh | Jun 2005 | A1 |
20050137688 | Salahieh et al. | Jun 2005 | A1 |
20050137692 | Haug | Jun 2005 | A1 |
20050137695 | Salahieh | Jun 2005 | A1 |
20050137701 | Salahieh | Jun 2005 | A1 |
20050143807 | Pavcnik et al. | Jun 2005 | A1 |
20050143809 | Salahieh | Jun 2005 | A1 |
20050148997 | Valley et al. | Jul 2005 | A1 |
20050149181 | Eberhardt | Jul 2005 | A1 |
20050165477 | Anduiza et al. | Jul 2005 | A1 |
20050187616 | Realyvasquez | Aug 2005 | A1 |
20050197695 | Stacchino et al. | Sep 2005 | A1 |
20050203549 | Realyvasquez | Sep 2005 | A1 |
20050203605 | Dolan | Sep 2005 | A1 |
20050203618 | Sharkawy | Sep 2005 | A1 |
20050222674 | Paine | Oct 2005 | A1 |
20050228495 | Macoviak | Oct 2005 | A1 |
20050234546 | Nugent | Oct 2005 | A1 |
20050240200 | Bergheim | Oct 2005 | A1 |
20050240263 | Fogarty et al. | Oct 2005 | A1 |
20050261759 | Lambrecht et al. | Nov 2005 | A1 |
20050283962 | Boudjemline | Dec 2005 | A1 |
20060004439 | Spenser et al. | Jan 2006 | A1 |
20060004469 | Sokel | Jan 2006 | A1 |
20060009841 | McGuckin et al. | Jan 2006 | A1 |
20060052867 | Revuelta et al. | Mar 2006 | A1 |
20060058775 | Stevens et al. | Mar 2006 | A1 |
20060089711 | Dolan | Apr 2006 | A1 |
20060100685 | Seguin et al. | May 2006 | A1 |
20060116757 | Lashinski et al. | Jun 2006 | A1 |
20060135964 | Vesely | Jun 2006 | A1 |
20060142848 | Gabbay | Jun 2006 | A1 |
20060167474 | Bloom et al. | Jul 2006 | A1 |
20060178740 | Stacchino et al. | Aug 2006 | A1 |
20060195134 | Crittenden | Aug 2006 | A1 |
20060206192 | Tower et al. | Sep 2006 | A1 |
20060206202 | Bonhoefer et al. | Sep 2006 | A1 |
20060212111 | Case et al. | Sep 2006 | A1 |
20060247763 | Slater | Nov 2006 | A1 |
20060259134 | Schwammenthal et al. | Nov 2006 | A1 |
20060259136 | Nguyen et al. | Nov 2006 | A1 |
20060259137 | Artof et al. | Nov 2006 | A1 |
20060265056 | Nguyen et al. | Nov 2006 | A1 |
20060271166 | Thill et al. | Nov 2006 | A1 |
20060271175 | Woolfson et al. | Nov 2006 | A1 |
20060276874 | Wilson et al. | Dec 2006 | A1 |
20060276882 | Case et al. | Dec 2006 | A1 |
20060282161 | Huynh et al. | Dec 2006 | A1 |
20070005129 | Damm et al. | Jan 2007 | A1 |
20070005131 | Taylor | Jan 2007 | A1 |
20070010878 | Raffiee et al. | Jan 2007 | A1 |
20070016286 | Herrmann et al. | Jan 2007 | A1 |
20070027518 | Case et al. | Feb 2007 | A1 |
20070027533 | Douk | Feb 2007 | A1 |
20070038295 | Case et al. | Feb 2007 | A1 |
20070043431 | Melsheimer | Feb 2007 | A1 |
20070043435 | Seguin et al. | Feb 2007 | A1 |
20070051377 | Douk et al. | Mar 2007 | A1 |
20070073392 | Heyninck-Janitz | Mar 2007 | A1 |
20070078509 | Lotfy et al. | Apr 2007 | A1 |
20070078510 | Ryan | Apr 2007 | A1 |
20070088431 | Bourang et al. | Apr 2007 | A1 |
20070093869 | Bloom et al. | Apr 2007 | A1 |
20070100439 | Cangialosi | May 2007 | A1 |
20070100440 | Figulla | May 2007 | A1 |
20070100449 | O'Neil et al. | May 2007 | A1 |
20070112415 | Bartlett | May 2007 | A1 |
20070162102 | Ryan et al. | Jul 2007 | A1 |
20070162113 | Sharkawy et al. | Jul 2007 | A1 |
20070185513 | Woolfson et al. | Aug 2007 | A1 |
20070203391 | Bloom et al. | Aug 2007 | A1 |
20070225681 | House | Sep 2007 | A1 |
20070232898 | Huynh et al. | Oct 2007 | A1 |
20070233228 | Eberhardt et al. | Oct 2007 | A1 |
20070233237 | Krivoruchko | Oct 2007 | A1 |
20070233238 | Huynh et al. | Oct 2007 | A1 |
20070238979 | Huynh et al. | Oct 2007 | A1 |
20070239254 | Marchand et al. | Oct 2007 | A1 |
20070239265 | Birdsall | Oct 2007 | A1 |
20070239266 | Birdsall | Oct 2007 | A1 |
20070239269 | Dolan et al. | Oct 2007 | A1 |
20070239273 | Allen | Oct 2007 | A1 |
20070244544 | Birdsall et al. | Oct 2007 | A1 |
20070244545 | Birdsall et al. | Oct 2007 | A1 |
20070244546 | Francis | Oct 2007 | A1 |
20070244553 | Rafiee et al. | Oct 2007 | A1 |
20070244554 | Rafiee et al. | Oct 2007 | A1 |
20070244555 | Rafiee et al. | Oct 2007 | A1 |
20070244556 | Rafiee et al. | Oct 2007 | A1 |
20070244557 | Rafiee et al. | Oct 2007 | A1 |
20070250160 | Rafiee | Oct 2007 | A1 |
20070255394 | Ryan | Nov 2007 | A1 |
20070255396 | Douk et al. | Nov 2007 | A1 |
20070288000 | Bonan | Dec 2007 | A1 |
20080004696 | Vesely | Jan 2008 | A1 |
20080009940 | Cribier | Jan 2008 | A1 |
20080015671 | Bonhoeffer | Jan 2008 | A1 |
20080021552 | Gabbay | Jan 2008 | A1 |
20080048656 | Tan | Feb 2008 | A1 |
20080065011 | Marchand et al. | Mar 2008 | A1 |
20080065206 | Liddicoat | Mar 2008 | A1 |
20080071361 | Tuval et al. | Mar 2008 | A1 |
20080071362 | Tuval et al. | Mar 2008 | A1 |
20080071363 | Tuval et al. | Mar 2008 | A1 |
20080071366 | Tuval et al. | Mar 2008 | A1 |
20080071368 | Tuval et al. | Mar 2008 | A1 |
20080077234 | Styrc | Mar 2008 | A1 |
20080082165 | Wilson et al. | Apr 2008 | A1 |
20080082166 | Styrc et al. | Apr 2008 | A1 |
20080133003 | Seguin et al. | Jun 2008 | A1 |
20080140189 | Nguyen et al. | Jun 2008 | A1 |
20080147105 | Wilson et al. | Jun 2008 | A1 |
20080147180 | Ghione et al. | Jun 2008 | A1 |
20080147181 | Ghione et al. | Jun 2008 | A1 |
20080147182 | Righini et al. | Jun 2008 | A1 |
20080154355 | Benichow et al. | Jun 2008 | A1 |
20080154356 | Obermiller et al. | Jun 2008 | A1 |
20080161910 | Revuelta et al. | Jul 2008 | A1 |
20080161911 | Revuelta et al. | Jul 2008 | A1 |
20080183273 | Mesana et al. | Jul 2008 | A1 |
20080188928 | Salahieh et al. | Aug 2008 | A1 |
20080215143 | Seguin et al. | Sep 2008 | A1 |
20080215144 | Ryan et al. | Sep 2008 | A1 |
20080228254 | Ryan | Sep 2008 | A1 |
20080228263 | Ryan | Sep 2008 | A1 |
20080234797 | Styrc | Sep 2008 | A1 |
20080243246 | Ryan et al. | Oct 2008 | A1 |
20080255651 | Dwork | Oct 2008 | A1 |
20080255660 | Guyenot et al. | Oct 2008 | A1 |
20080255661 | Straubinger et al. | Oct 2008 | A1 |
20080262593 | Ryan et al. | Oct 2008 | A1 |
20080269878 | Iobbi | Oct 2008 | A1 |
20090005863 | Goetz et al. | Jan 2009 | A1 |
20090012600 | Styrc et al. | Jan 2009 | A1 |
20090048656 | Wen | Feb 2009 | A1 |
20090054976 | Tuval et al. | Feb 2009 | A1 |
20090069886 | Suri et al. | Mar 2009 | A1 |
20090069887 | Righini et al. | Mar 2009 | A1 |
20090069889 | Suri et al. | Mar 2009 | A1 |
20090085900 | Weiner | Apr 2009 | A1 |
20090099653 | Suri et al. | Apr 2009 | A1 |
20090138079 | Tuval et al. | May 2009 | A1 |
20090164004 | Cohn | Jun 2009 | A1 |
20090171447 | VonSeggesser et al. | Jul 2009 | A1 |
20090192585 | Bloom et al. | Jul 2009 | A1 |
20090192586 | Tabor et al. | Jul 2009 | A1 |
20090192591 | Ryan et al. | Jul 2009 | A1 |
20090198316 | Laske et al. | Aug 2009 | A1 |
20090216310 | Straubinger et al. | Aug 2009 | A1 |
20090216312 | Straubinger et al. | Aug 2009 | A1 |
20090216313 | Straubinger et al. | Aug 2009 | A1 |
20090234443 | Ottma et al. | Sep 2009 | A1 |
20090240264 | Tuval et al. | Sep 2009 | A1 |
20090240320 | Tuval | Sep 2009 | A1 |
20090287296 | Manasse | Nov 2009 | A1 |
20100036479 | Hill et al. | Feb 2010 | A1 |
20100094411 | Tuval et al. | Apr 2010 | A1 |
20100100167 | Bortlein et al. | Apr 2010 | A1 |
20100131054 | Tuval et al. | May 2010 | A1 |
20100137979 | Tuval et al. | Jun 2010 | A1 |
20100161045 | Righini | Jun 2010 | A1 |
20100234940 | Dolan | Sep 2010 | A1 |
Number | Date | Country |
---|---|---|
2007-100074433 | Aug 2007 | CN |
3640745 | Jun 1987 | DE |
195 32 846 | Mar 1997 | DE |
195 46 692 | Jun 1997 | DE |
195 46 692 | Jun 1997 | DE |
198 57 887 | Jul 2000 | DE |
199 07 646 | Aug 2000 | DE |
100 49 812 | Apr 2002 | DE |
100 49 813 | Apr 2002 | DE |
100 49 815 | Apr 2002 | DE |
1057460 | Jun 2000 | EP |
1255510 | Nov 2002 | EP |
1469797 | Nov 2005 | EP |
2788217 | Dec 1999 | FR |
2815844 | May 2000 | FR |
2056023 | Mar 1981 | GB |
2433700 | Dec 2007 | GB |
1271508 | Nov 1986 | SU |
9529640 | Nov 1995 | WO |
WO 00-12032 | Mar 2000 | WO |
0047136 | Aug 2000 | WO |
0135870 | May 2001 | WO |
0149213 | Jul 2001 | WO |
0154625 | Aug 2001 | WO |
0162189 | Aug 2001 | WO |
0164137 | Sep 2001 | WO |
0222054 | Mar 2002 | WO |
0236048 | May 2002 | WO |
WO 02-49546 | Jun 2002 | WO |
03003943 | Jan 2003 | WO |
03003949 | Jan 2003 | WO |
03011195 | Feb 2003 | WO |
WO 03-047468 | Jun 2003 | WO |
2004019825 | Mar 2004 | WO |
2004089250 | Oct 2004 | WO |
2005004753 | Jan 2005 | WO |
WO 2005-046528 | May 2005 | WO |
2006026371 | Mar 2006 | WO |
2008047354 | Apr 2008 | WO |
2008138584 | Nov 2008 | WO |
2008150529 | Dec 2008 | WO |
2009002548 | Dec 2008 | WO |
2009029199 | Mar 2009 | WO |
2009042196 | Apr 2009 | WO |
2009045338 | Apr 2009 | WO |
2009061389 | May 2009 | WO |
2009091509 | Jul 2009 | WO |
2009111241 | Sep 2009 | WO |
Entry |
---|
Andersen, H.R. et al, “Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs.” Euro. Heart J. (1992) 13:704-708. |
Babaliaros, et al., “State of the Art Percutaneous Intervention for the Treatment of Valvular Heart Disease: A Review of the Current Technologies and Ongoing Research in the Field of Percutaneous Heart Valve Replacement and Repair,” Cardiology 2007; 107:87-96. |
Bailey, “Percutaneous Expandable Prosthetic Valves,” in: Topol EJ, ed. Textbook of Interventional Cardiology. Volume II. Second edition. WB Saunders, Philadelphia, 1994:1268-1276. |
Block, et al., “Percutaneous Approaches to Valvular Heart Disease,” Current Cardiology Reports, vol. 7 (2005) pp. 108-113. |
Bonhoeffer, et al, “Percutaneous Insertion of the Pulmonary Valve,” Journal of the American College of Cardiology (United States), May 15, 2002, pp. 1664-1669. |
Bonhoeffer, et al, “Percutaneous Replacement of Pulmonary Valve in a Right-Ventricle to Pulmonary-Artery Prosthetic Conduit with Valve Dysfunction,” Lancet (England), Oct. 21, 2000, pp. 1403-1405. |
Bonhoeffer, et al, “Transcatheter Implantation of a Bovine Valve in Pulmonary Position: A Lamb Study,” Circulation (United States), Aug. 15, 2000, pp. 813-816. |
Boudjemline, et al, “Images in Cardiovascular Medicine. Percutaneous Aortic Valve Replacement in Animals,” Circulation (United States), Mar. 16, 2004, 109, p. e161. |
Boudjemline, et al, “Is Percutaneous Implantation of a Bovine Venous Valve in the Inferior Vena Cava a Reliable Technique to Treat Chronic Venous Insufficiency Syndrome?” Medical Science Monitor—International Medical Journal of Experimental and Clinical Research (Poland), Mar. 2004, pp. BR61-BR66. |
Boudjemline, et al, “Off-pump Replacement of the Pulmonary Valve in Large Right Ventricular Outflow Tracts: A Hybrid Approach,” Journal of Thoracic and Cardiovascular Surgery (United States), Apr. 2005, pp. 831-837. |
Boudjemline, et al, “Percutaneous Aortic Valve Replacement: Will We Get There?” Heart (British Cardiac Society) (England), Dec. 2001, pp. 705-706. |
Boudjemline, et al, “Percutaneous Implantation of a Biological Valve in the Aorta to Treat Aortic Valve Insufficiency—A Sheep Study,” Medical Science Monitor—International Medical Journal of Experimental and Clinical Research (Poland), Apr. 2002, pp. BR113-BR116. |
Boudjemline, et al, “Percutaneous Implantation of a Biological Valve in Aortic Position: Preliminary Results in a Sheep Study,” European Heart Journal 22, Sep. 2001, p. 630. |
Boudjemline, et al, “Percutaneous Implantation of a Valve in the Descending Aorta in Lambs,” European Heart Journal (England), Jul. 2002, pp. 1045-1049. |
Boudjemline, et al, “Percutaneous Pulmonary Valve Replacement in a Large Right Ventricular Outflow Tract: An Experimental Study,” Journal of the American College of Cardiology (United States), Mar. 17, 2004, pp. 1082-1087. |
Boudjemline, et al, “Percutaneous Valve Insertion: A New Approach,” Journal of Thoracic and Cardiovascular Surgery (United States), Mar. 2003, pp. 741-742. |
Boudjemline, et al, “Stent Implantation Combined with a Valve Replacement to Treat Degenerated Right Ventricle to Pulmonary Artery Prosthetic Conduits,” European Heart Journal 22, Sep. 2001, p. 355. |
Boudjemline, et al, “Steps Toward Percutaneous Aortic Valve Replacement,” Circulation (United States), Feb. 12, 2002, pp. 775-778. |
Boudjemline, et al, “The Percutaneous Implantable Heart Valve,” Progress in Pediatric Cardiology (Ireland), 2001, pp. 89-93. |
Boudjemline, et al, “Transcatheter Reconstruction of the Right Heart,” Cardiology in the Young (England), Jun. 2003, pp. 308-311. |
Coats, et al, “The Potential Impact of Percutaneous Pulmonary Valve Stent Implantation on Right Ventricular Outflow Tract Re-Intervention,” European Journal of Cardio-Thoracic Surgery (England), Apr. 2005, pp. 536-543. |
Cribier, A. et al, “Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case Description,” Circulation (2002) 3006-3008. |
Davidson et al., “Percutaneous therapies for valvular heart disease,” Cardiovascular Pathology 15 (2006) 123-129. |
Hanzel, et al., “Complications of percutaneous aortic valve replacement: experience with the Criber-Edwards™ percutaneous heart valve,” EuroIntervention Supplements (2006), 1 (Supplement A) A3-A8. |
Huber, et al., “Do Valved Stents Compromise Coronary Flow?” Eur. J. Cardiothorac. Surg. 2004;25:754-759. |
Khambadkone, “Nonsurgical Pulmonary Valve Replacement: Why, When, and How?” Catheterization and Cardiovascular Interventions—Official Journal of the Society for Cardiac Angiography & Interventions (United States), Jul. 2004, pp. 401-408. |
Khambadkone, et al, “Percutaneous Implantation of Pulmonary Valves,” Expert Review of Cardiovascular Therapy (England), Nov. 2003, pp. 541-548. |
Khambadkone, et al, “Percutaneous Pulmonary Valve Implantation: Early and Medium Term Results,” Circulation 108 (17 Supplement), Oct. 28, 2003, p. IV-375. |
Khambadkone, et al, “Percutaneous Pulmonary Valve Implantation: Impact of Morphology on Case Selection,” Circulation 108 (17 Supplement), Oct. 28, 2003, p. IV-642-IV-643. |
Lutter, et al, “Percutaneous Aortic Valve Replacement: An Experimental Study. I. Studies on Implantation,” The Journal of Thoracic and Cardiovascular Surgery, Apr. 2002, pp. 768-776. |
Lutter, et al, “Percutaneous Valve Replacement: Current State and Future Prospects,” Annals of Thoracic Surgery (Netherlands), Dec. 2004, pp. 2199-2206. |
Medtech Insight, “New Frontiers in Heart Valve Disease,” vol. 7, No. 8 (2005). |
Palacios, “Percutaneous Valve Replacement and Repair, Fiction or Reality?” Journal of American College of Cardiology, vol. 44, No. 8 (2004) pp. 1662-1663. |
Pelton et al., “Medical Uses of Nitinol,” Materials Science Forum vols. 327-328, pp. 63-70 (2000). |
Ruiz, “Transcathether Aortic Valve Implantation and Mitral Valve Repair: State of the Art,” Pediatric Cardiology, vol. 26, No. 3 (2005). |
Saliba, et al, “Treatment of Obstructions of Prosthetic Conduits by Percutaneous Implantation of Stents,” Archives des Maldies du Coeur et des Vaisseaux (France), 1999, pp. 591-596. |
Webb, et al., “Percutaneous Aortic Valve Implantation Retrograde from the Femoral Artery,” Circulation (2006), 113;842-850. |
Stassano et al., “Mid-term results of the valve-on-valve technique for bioprosthetic failure,” Eur. J. Cardiothorac. Surg. 2000; 18:453-457. |
Expert report of Dr. Nigel Buller, dated Jan. 12, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (83 pages). |
Expert report of Dr. Nigel Buller, non-confidential annex—infringement, dated Jan. 12, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (12 pages). |
Expert report of Dr. Rodolfo Quijano, dated Jan. 9, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (18 pages). |
First Expert report of Prof. David Williams, dated Jan. 12, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (41 pages). |
First Expert report of Prof. Martin Rothman, dated Jan. 12, 2009, Edwards Lifesciences and Cook Biotech, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (64 pages). |
Fourth Expert report of Prof. Martin Rothman, dated Apr. 22, 2009, Edwards Lifesciences and Cook Biotech, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (10 pages). |
Second Expert report of Dr. Nigel Buller, dated Feb. 25, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (24 pages). |
Second Expert report of Dr. Rodolfo Quijano, dated Feb. 26, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (6 pages). |
Second Expert report of Prof. David Williams, dated Feb. 5, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (15 pages). |
Second Expert report of Prof. Martin Rothman, dated Feb. 5, 2009, Edwards Lifesciences and Cook Biotech, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (11 pages). |
Third Expert report of Dr. Nigel Buller, dated Apr. 21, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (6 pages). |
Third Expert report of Dr. Rudolfo Quijano, dated Apr. 27, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (3 pages). |
Third Expert report of Prof. David Williams, dated Apr. 22, 2009, Edwards' United Kingdom action for invalidity, Claim No. HC 08CO0934 (9 pages). |
Pavcnik et al., “Aortic and venous valve for percutaneous insertion,” Min. Invas. Ther. & Allied Techol. 2000, vol. 9, pp. 287-292. |
First Expert report of Dr. Nigel Person Buller (30 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
Second Expert report of Dr. Nigel Person Buller (5 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
Drawing by Dr. Buller (Edwards Expert) of “higher stent” on the schematic representation of the aortic valve area set out in Figure 2 of Rothman's first expert report (1 page), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
First Expert report of Professor John R. Pepper (20 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
Second Expert report of Professor John R. Pepper (3 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
First Expert report of Dr. Anthony C. Lunn (7 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
First Witness statement of Stanton Rowe (9 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
Second Witness statement of Stanton Rowe (3 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
PVT slides naming Alain Cribier, Martin Leon, Stan Rabinovich and Stanton Rowe (16 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
Expert Rebuttal Report of Prof. Martin T. Rothman (32 pages) redacted, Edwards v. Core Valve, U.S. District Court, District of Delaware, Case No. 08-091, dated Jul. 29, 2009. |
Expert Report of Prof. Martin T. Rothman (74 pages) redacted, Edwards v. CoreValve, U.S. District Court, District of Delaware, Case No. 08-091, dated Jun. 29, 2009. |
First Expert report of Richard A. Hillstead (41 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
Reply Expert report of Richard A. Hillstead (9 pages), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
Drawing by Dr. Buller (Edwards Expert) of his interpretation of the “higher stent” referred to at col. 8, lines 13-222 of Andersen EP 592410B1 (1 page), Corevalve, Inc. v. Edwards Lifesciences AG and Edwards Lifesciences PVT, Inc., High Court of Justice—Chancery Division Patents Court, United Kingdom, Case No. HC-07-C01243. |
Number | Date | Country | |
---|---|---|---|
20070270944 A1 | Nov 2007 | US |
Number | Date | Country | |
---|---|---|---|
60565118 | Apr 2004 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11112757 | Apr 2005 | US |
Child | 11685025 | US |